Research Article

A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study

Table 4

Demographics and laboratory data assessment of according to symptom recovery.

ParametersRecovered-symptoms group (n = 50)Persisted-symptoms group (n = 55)-value

Age (yr), mean (SD)39.58 (15.33)39.21 (16.4)0.908

Sex
Male, n29410.072
Female, n2114
BMI, mean (SD)24.55 (2.78)24.59 (2.69)24.57 (2.7)

Comorbidity
Smoking, n (%)03 (5.5)1.0
Addiction, n (%)01 (1.9)1.0
DM, n (%)5 (10)4 (7.3)0.73
HTN, n (%)6 (12)5 (9.1)0.75
DLP, n (%)8 (16)2 (3.6)0.05
IHD, n (%)1 (2)1 (1.8)1.0
Thyroid disorder, n (%)3 (6)5 (9.1)0.72
Depression, n (%)2 (4)00.22
Alzheimer, n (%)1 (2)00.48
Asthma, n (%)2 (4)4 (7.3)0.68
Sinusitis, n(%)2 (4)1 (1.8)0.60
IBD, n (%)1 (2)1 (1.8)1.0
Allergy history, n (%)6 (12)4 (7.3)0.51
Symptom onset (days), mean (SD)5.62 (1.52)5.58 (2.02)0.91

Lab tests
CRP, mean (SD)18.4 (21.4)14.61 (10.94)0.44
WBC, mean (SD)5792.92 (1981.9)5736.72 (2597.7)0.41
Lymphocyte, mean (SD)1577.18 (896.17)1534.12 (78.32)0.79
Neutrophil, mean (SD)3690.36 (1638.6)3634.85 (1869.85)0.44
Platelet, mean (SD)195640 (6119.1)187963.64 (73705.1)0.56
Platelet-to-lymphocyte ratio, mean (SD)202.04 (371.53)146.82 (86.86)0.38
Neutrophil-to-lymphocyte ratio, mean (SD)4.58 (12.19)2.74 (1.58)0.87
Hemoglobin11.98 (0.9)12.3 (1.09)0.86

BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; DLP: dyslipidemia; IHD: ischemic heart disease; IBD: irritable bowel disease; AD: Alzheimer disease; SD: standard deviation.